申请人:Abbott Laboratories
公开号:US04634705A1
公开(公告)日:1987-01-06
Disclosed herein are adrenergic compounds represented by the formula ##STR1## wherein m is 0, 1 or 2; R.sub.1, R.sub.2, R.sub.3 and R.sub.7 are taken from the group consisting of hydrogen, hydroxy, loweralkyl, loweralkoxy, halo, amino, acetamido or NHSO.sub.2 R wherein R is taken from the group consisting of hydrogen or loweralkyl, provided that R.sub.1, R.sub.2, R.sub.3 and R.sub.7 cannot simultaneously be hydrogen or halo, and provided that when one of R.sub.1, R.sub.2, R.sub.3 and R.sub.7 is halo, the others cannot simultaneously be hydrogen and when two of R.sub.1, R.sub.2, R.sub.3 and R.sub.7 are halo, the other two cannot simultaneously be hydrogen and provided that R.sub.1 and R.sub.7 cannot simultaneously be methoxy each when R.sub.2 and R.sub.3 are hydrogen; R.sub.1 and R.sub.2 or R.sub.2 and R.sub.3 or R.sub.3 and R.sub.7 taken together can form a methylenedioxy or ethylenedioxy bridge; or R.sub.1 and R.sub.2 or R.sub.2 and R.sub.3 or R.sub.3 and R.sub.7 taken together with the aromatic ring can form a benzimidazole or indole bridge; and R.sub.4 and R.sub.5 are hydrogen or taken together form a closed ring of the formula ##STR2## wherein n is 1 or 2, and the combined solid and dashed line represents a single or double bond when n is 1, and R.sub.6 is taken from the group consisting of hydrogen or loweralkyl, and the pharmaceutically acceptable salts thereof.
本文公开了由以下公式表示的肾上腺素化合物:##STR1## 其中m为0、1或2;R.sub.1、R.sub.2、R.sub.3和R.sub.7取自氢、羟基、低烷基、低烷氧基、卤素、氨基、乙酰胺基或NHSO.sub.2R的群,其中R取自氢或低烷基,前提是R.sub.1、R.sub.2、R.sub.3和R.sub.7不能同时为氢或卤素,且当R.sub.1、R.sub.2、R.sub.3和R.sub.7中的一个为卤素时,其他的不能同时为氢,当R.sub.1、R.sub.2、R.sub.3和R.sub.7中的两个为卤素时,另外两个不能同时为氢,且当R.sub.1和R.sub.7同时为甲氧基时,R.sub.2和R.sub.3都为氢;R.sub.1和R.sub.2或R.sub.2和R.sub.3或R.sub.3和R.sub.7可以组成亚甲二氧基或乙二氧基桥;或者R.sub.1和R.sub.2或R.sub.2和R.sub.3或R.sub.3和R.sub.7与芳环一起可以形成苯并咪唑或吲哚桥;R.sub.4和R.sub.5为氢或一起形成以下公式的闭合环:##STR2## 其中n为1或2,当n为1时,实线和虚线组成单键或双键;R.sub.6取自氢或低烷基,以及其药学上可接受的盐。